ClinicalTrials.gov
ClinicalTrials.gov Menu

Mesenchymal Stromal Cells for Haplo Hematopoietic Cell Transplantation for Sickle Cell Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03298399
Recruitment Status : Recruiting
First Posted : October 2, 2017
Last Update Posted : May 17, 2018
Sponsor:
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Elizabeth Stenger, Emory University

Brief Summary:
This trial is being conducted as a step toward testing the long-term hypothesis that freshly cultured, autologous mesenchymal stromal cells (MSCs) grown in platelet lysate-containing medium will modulate recipient T-cell immune responses and promote engraftment in haploidentical hematopoietic cell transplant (HCT) recipients. As a phase I, dose escalation trial of autologous MSCs in patients with sickle cell disease (SCD) undergoing haploidentical HCT, the main aim is to evaluate the safety of this therapy with a secondary aim to evaluate its effects on engraftment and graft-versus-host disease (GVHD).

Condition or disease Intervention/treatment Phase
Sickle Cell Disease Biological: Autologous MSCs Phase 1

Detailed Description:

This is a single center, phase I, open label dose escalation study designed to determine the safety and tolerability of autologous, bone marrow-derived MSCs (EPIC2016-MSC003) in patients with SCD undergoing haploidentical HCT.

Study participants are assigned to one of three MSC dose levels: four infusions of MSCs given once per week, four infusions given twice per week, or six infusions given twice per week. Bone marrow (1-2 ml/kg, max 60 ml) will be collected from study participants for autologous MSC expansion a minimum of 28 days prior to first planned MSC infusion. MSCs will be expanded ex vivo in human platelet lysate to the specified dose level. All MSC infusions will be dosed at 2 x 10^6 MSCs/kg recipient weight, with first infusion given on day 0 (day of haploidentical HCT) or day +1. This phase I trial will enroll 12-18 patients with severe SCD undergoing haploidentical HCT, with subjects followed for 1 year following HCT (and MSC infusions).

Prior to MSC infusions, study participants will undergo transplant conditioning and GVHD prophylaxis as follows:

Day -100 to -10: Hydroxyurea 30 mg/kg PO Qday

Day -9: Rabbit anti-thymocyte globulin (ATG) 0.5 mg/kg IV

Day -8: Rabbit ATG 2 mg/kg IV

Day -7: Rabbit ATG 2 mg/kg IV; Thiotepa 10 mg/kg IV

Day -6: Fludarabine 30 mg/m2 IV; Cyclophosphamide 14.5 mg/kg IV

Day -5: Fludarabine 30 mg/m2 IV; Cyclophosphamide 14.5 mg/kg IV

Day -4: Fludarabine 30 mg/m2 IV

Day -3: Fludarabine 30 mg/m2 IV

Day -2: Fludarabine 30 mg/m2 IV

Day -1: Total body irradiation (TBI) 200 centigray (cGy)

Day 0: Haploidentical bone marrow stem cell infusion

Day +3: Cyclophosphamide 50 mg/kg IV

Day +4: Cyclophosphamide 50 mg/kg IV

Day +5: Sirolimus (through day +365); mycophenolate mofetil (MMF) 15 mg/kg/dose three times per day (TID) (through day +35)


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Mesenchymal Stromal Cells to Promote Stem Cell Engraftment in Patients With Severe Sickle Cell Disease Undergoing Haploidentical Hematopoietic Cell Transplantation
Actual Study Start Date : December 21, 2017
Estimated Primary Completion Date : September 1, 2021
Estimated Study Completion Date : September 1, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: MSC dose level 1
The first three subjects (minimum) will receive four weekly infusions of MSCs.
Biological: Autologous MSCs
Participants at dose level 1 receive four infusions of MSCs, given once per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.

Experimental: MSC dose level 2
If no significant side effects are encountered at dose level 1, then subsequent subjects will receive four infusions of MSCs given twice weekly.
Biological: Autologous MSCs
Participants at dose level 2 receive four infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.

Experimental: MSC dose level 3
If dose level 2 is well tolerated, then subsequent subjects will receive six infusions MSCs given twice weekly.
Biological: Autologous MSCs
Participants at dose level 3 receive six infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.




Primary Outcome Measures :
  1. Safety and tolerability of EPIC2016-MSC003 based upon dose limiting toxicities (DLTs) [ Time Frame: 30 days after last MSC infusion ]
    DLTs will be defined as any grade ≥3 adverse reaction that is unexpected or considered attributable to the MSC infusion (attribution listed as at least probable). Because of the medical complexity of subjects on this trial and the lack of described DLTs to MSC infusion, all reported DLTs will be reviewed by the Data and Safety Monitoring Committee (DSMC).


Secondary Outcome Measures :
  1. Primary graft rejection [ Time Frame: 42 days after HCT ]
    Defined as the absence of donor cells assessed by peripheral blood chimerism assays on day 42.

  2. Late graft rejection [ Time Frame: One year after HCT ]
    Defined as the absence of donor hematopoietic cells in peripheral blood beyond day 42 in a patient who had initial evidence of hematopoietic recovery with > 20% donor cells.

  3. Time to neutrophil engraftment [ Time Frame: Up to one year after HCT ]
    Defined as the first of 3 measurements on different days when the patient has an absolute neutrophil count of 500/µL after conditioning.

  4. Time to platelet engraftment [ Time Frame: Up to one year after HCT ]
    Defined as the first day of a minimum of 3 measurements on different days that the patient has achieved a platelet count > 50,000/µL AND did not receive a platelet transfusion in the previous 7 days.

  5. Lineage specific donor chimerism [ Time Frame: Up to one year after HCT ]
    Genomic deoxyribonucleic acid (DNA) extracted from peripheral blood will be analyzed for variable number of tandem repeats (VNTR) to detect donor engraftment in myeloid and lymphoid fractions.

  6. Immune reconstitution [ Time Frame: Up to one year after HCT ]
    Immune reconstitution will be assessed post-transplant by standard clinical testing and research testing.

  7. Acute GVHD [ Time Frame: One year after HCT ]
    Incidence of grade II-IV and III-IV acute GVHD

  8. Chronic GVHD [ Time Frame: One year after HCT ]
    Incidence and severity of chronic GVHD

  9. Transplant-related mortality (TRM) [ Time Frame: One year after HCT ]
    Defined as any death occurring in continuous complete remission

  10. Event-free survival (EFS) [ Time Frame: One year after HCT ]
    Defined as survival with stable donor erythropoiesis and no new clinical evidence SCD. Primary or late graft rejection with disease recurrence or death will count as events for this endpoint.

  11. Overall survival (OS) [ Time Frame: One year after HCT ]
    Defined as survival with or without SCD after HCT



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must weigh >25 kg at the time of study entry.
  • Must have undergone puberty at the time of study entry to allow pre-transplant fertility preservation to occur, if desired. Puberty will be defined as Tanner III or more in male patients (typically age ≥ 13 years) and menarche in female patients.
  • Have severe sickle cell disease (SCD) defined as 1 or more of the following:

    1. Clinically significant neurologic event (stroke) or any neurological deficit lasting > 24 hours;
    2. History of ≥2 episodes of acute chest syndrome (ACS) in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. asthma therapy and/or hydroxyurea);
    3. History of ≥3 severe pain crises per year in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. a pain management plan and/or treatment with hydroxyurea);
    4. Administration of regular red blood cell (RBC) transfusion therapy, defined as receiving ≥8 transfusions per year for ≥1 year to prevent vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest syndrome);
    5. An echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity ≥2.7 m/sec in adult patients.
  • Have adequate physical function as measured by:

    1. Lansky or Karnofsky performance score ≥60
    2. Cardiac function: left ventricular ejection fraction (LVEF) >40% or LV shortening fraction > 26% by cardiac echocardiogram or by multigated acquisition (MUGA) scan.
    3. Pulmonary function: pulse oximetry with a baseline O2 saturation of ≥90% and DLCO >40% (corrected for hemoglobin)
    4. Renal function: serum creatinine ≤1.5 x the upper limit of normal for age as per local laboratory and 24 hour urine creatinine clearance >70 mL/min/1.73 m2 or glomerular filtration rate (GFR) >70 mL/min/1.73 m2 by radionuclide GFR.
    5. Hepatic function: serum conjugated (direct) bilirubin <2x upper limit of normal for age as per local laboratory and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <5x upper limit of normal as per local laboratory. Patients with hyperbilirubinemia as a consequence of hyperhemolysis or who experience a sudden, profound change in the serum hemoglobin after a RBC transfusion are not excluded.
    6. In patients who have received chronic transfusion therapy for ≥1 year and who have clinical evidence of iron overload by serum ferritin or MRI, evaluation by liver biopsy is required. Histological examination of the liver must document the absence of cirrhosis, bridging fibrosis and active hepatitis. The absence of bridging fibrosis will be determined using the histological grading and staging scale as described by Ishak and colleagues (1995).
  • Must be HLA typed at high resolution using DNA based typing at HLA-A, -B, -C and DRB1 and have an available related haploidentical bone marrow donor with 2, 3, or 4 (out of 8) HLA-mismatches. A unidirectional mismatch in either the graft versus host or host versus graft direction is considered a mismatch.

Exclusion Criteria:

  • Availability of an 8 of 8 (HLA-A, B, C and DRB1) human leukocyte antigen (HLA) matched sibling or matched unrelated donor
  • Presence of donor directed HLA antibodies.
  • Severe pulmonary disease (despite above oxygen saturation and DLCO) including severe and uncontrolled asthma (per 2007 NHLBI Guidelines for the Diagnosis and Treatment of Asthma Expert Panel Report 3; http://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines/full-report), chronic obstructive pulmonary disease, and/or pulmonary hypertension (PH). A diagnosis of pulmonary hypertension (PH) will be made by finding of mean pulmonary artery pressure (mPAP) <25 mm Hg on right heart catheterization. In patients unable and/or unwilling to undergo cardiac catheterization, patients will be excluded with the following constellation of findings based upon presumptive diagnosis of PH (PPV of 62%): TRJ velocity >2.5 m/sec AND either N-terminal pro-brain natriuretic peptide (NT-pro-BNP) ≥160 pg/ml OR 6-minute walk distance <333 m.
  • Uncontrolled bacterial, viral or fungal infection in the 6 week before enrollment
  • Seropositivity for human immunodeficiency virus (HIV)
  • Previous hematopoietic cell transplantation (HCT)
  • Participation in a clinical trial in which the patient received an investigational drug or device or the off-label use of a drug or device within 3 months of enrollment
  • Demonstrated lack of compliance with prior medical care
  • Unwilling to use approved contraception for at least 6 months following transplant
  • Pregnant or breastfeeding females
  • Allergy to any component of mesenchymal stromal cell (MSC) suspension (such as human albumin) and/or allergy to any drugs used in HCT conditioning regimen.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03298399


Contacts
Contact: Elizabeth Stenger, MD, MSc 404-785-1272 elizabeth.stenger@choa.org
Contact: Chanta Whitlow 4047850696 chanta.whitlow@choa.org

Locations
United States, Georgia
Children's Healthcare of Atlanta (CHOA) Active, not recruiting
Atlanta, Georgia, United States, 30322
Emory University Winship Cancer Institute Recruiting
Atlanta, Georgia, United States, 30322
Contact: Megan Hanby, RN    404-785-7749      
Contact: Elizabeth Stenger, MD, MSc    404-785-1272      
Sub-Investigator: Edmund Waller, MD, PhD         
Sub-Investigator: Zaid Al-Kadhimi, MD         
Sub-Investigator: Amelia Langston, MD         
Sponsors and Collaborators
Emory University
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Principal Investigator: Elizabeth Stenger, MD Emory University
Principal Investigator: Lakshmanan Krishnamurti, MD Emory University

Responsible Party: Elizabeth Stenger, Assistant Professor, Emory University
ClinicalTrials.gov Identifier: NCT03298399     History of Changes
Other Study ID Numbers: IRB00090514
1K23HL133446 ( U.S. NIH Grant/Contract )
First Posted: October 2, 2017    Key Record Dates
Last Update Posted: May 17, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Elizabeth Stenger, Emory University:
Hematopoietic cell transplantation (HCT)
Haploidentical
Mesenchymal stromal cells

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn